9.095USD+7.38%Mkt Cap: 945.11M USDP/E: —Last update: 2026-05-26
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of mi…
Industry Peers
Diagnostics & Research166.94BUSDP/E 24.7
122.72BUSDP/E 33.6
44.05BUSDP/E 41.1
34.42BCHFP/E 37.9
33.46BUSDP/E 43.3
32.69BUSDP/E 25.5
28.46BUSD—
27.28BUSDP/E 20.3
Indicators:|
Key Statistics
Company
Market Cap945.11M USD
Enterprise Value669.51M USD
Revenue (TTM)64.52M USD
Gross Profit15.78M USD
Net Income (TTM)-81.27M USD
Revenue/Share0.6910 USD
Last Price9.095 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees259
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.21
PEG—
EV/EBITDA-7.22
EV/Revenue10.38
P/S13.39
P/B3.39
EPS (TTM)-1.02
EPS (Forward)-0.90
52W Range
3.84069% of range11.50
52W High11.50 USD
52W Low3.840 USD
Profitability
Gross Margin22.65%
Oper. Margin-207.87%
EBITDA Margin-143.68%
Profit Margin-116.69%
ROE-31.12%
ROA-24.32%
Growth
Revenue Growth-24.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.95M USD
CapEx (TTM)4.50M USD
FCF Margin-65.65%
FCF Yield-4.48%
Net Debt-194.44M USD
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity0.15
Current Ratio6.61
Quick Ratio6.31
Book Value/Sh2.433 USD
Cash/Share2.227 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)10.86 USD
Target Range9.000 USD – 13.00 USD
# Analysts7
Ownership
Shares Out.104.72M
Float62.48M
Insiders27.05%
Institutions70.13%
Short Interest
Short Ratio7.2d
Short % Float19.76%
Short % Out.12.51%
Shares Short13.10M
Short (prev mo.)11.76M
Technical
SMA 506.495 (+40.0%)
SMA 2007.532 (+20.8%)
Beta1.97
S&P 52W Chg28.31%
Avg Vol (30d)2.35M
Avg Vol (10d)2.79M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—